|
Adding precision to 2018 ASCO/CAP HER2 testing guidelines in breast cancer with genomic profiling. |
|
|
Consulting or Advisory Role - Agendia; Bayer; Bioarray Therapeutics; bioTheranostics; Celgene; Eisai; Genentech/Roche; Genomic Health; Lilly; Merck; Myriad Pharmaceuticals; NanoString Technologies; Novartis; Pfizer; Puma Biotechnology |
|
|
No Relationships to Disclose |
|
|
Employment - Radiation Oncology Specialists |
Stock and Other Ownership Interests - Merck; Romeo Plank Partners |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Agendia |
|
|
|
Stock and Other Ownership Interests - Agendia |
Patents, Royalties, Other Intellectual Property - NXT Biologics |
|
|
|
Stock and Other Ownership Interests - Agendia |
|
|
No Relationships to Disclose |